HCV genotype 4 patients achieved SVR12 with triple therapy

  • May 23, 2014

CHICAGO — Hepatitis C virus genotype 4-infected patients met sustained virologic response at 12 weeks with an all-oral triple therapy of daclatasvir, asunaprevir and the non-nucleoside NS5B inhibitor BMS-791325, according to research presented at Digestive Disease Week 2014.

Researcher Tarek Hassanein, MD, of the Southern California Liver Centers, and colleagues randomly assigned 21 treatment-naive hepatitis C virus genotype 4-infected patients to either 30 mg daclatasvir, 200 mg asunaprevir, and 75 mg BMS-791325 (Bristol-Myers Squibb; n=11) twice daily or 150 mg BMS-791325 (n=10) twice daily for 12 weeks. Patients were primarily men (62%), white (91%) and noncirrhotic.

More »

Additional headlines from Digestive Disease Week

See All »